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Background: Multiple comorbidities related to chronic obstructive pulmonary disease (COPD)
make it a difficult disease to treat. The relationship between these comorbidities and COPD
has not been fully investigated. We aimed to determine whether COPD was independently
associated with various comorbidities.
Methods: This was a cross-sectional study, which used data from the Korean National Health
and Nutrition Examination Survey (KNHANES) V conducted between 2010 and 2012. Survey
design analysis was employed to determine the association between COPD and 15 comorbid-
ities. A COPD patient was defined as a smoker with forced expiratory volume in 1 s (FEV1)/
forced vital capacity (FVC) < 0.7 and comorbidities were defined based on objective labora-
tory findings and questionnaires.
Results: Of a total of 9488 patient who underwent spirometry, 744 (7.84%) COPD cases and
3313 non-COPD controls were included in the analyses. Although the prevalence rates of the
majority of the comorbidities were high among the COPD patients, only hypertension (adjusted
odds ratio [aOR], 1.63; 95% CI, 1.13e2.33 in Stage 1 COPD group; aOR, 1.92; 95% CI, 1.36e2.72
in Stage 2e4 COPD group) and a history of pulmonary tuberculosis (aOR, 3.38; 95% CI, 1.90tio; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; FEV1, forced expiratory
ity; KNHANES, Korean National Health and Nutrition Examination Survey.
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The relationship between chronic obstructive pulmonary disease and comorbidities 97e5.99 in Stage 2e4 COPD group) were independently associated with COPD after adjustment
for age, smoking status, and confounders.
Conclusions: Only hypertension and a history of pulmonary tuberculosis were independently
associated with COPD after adjustment for confounders among 15 comorbidities. The results
suggest that majority of COPD patients might have similar risk factors with its comorbidities,
including age and smoking status.
ª 2014 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality worldwide, and its prev-
alence is increasing. At present, it is the fourth most
common cause of death in the U.S., and it is expected to
become the third most common cause by 2020 [1]. Without
interventions to eliminate risk factors for COPD, especially
tobacco smoke [1], deaths from COPD are projected to in-
crease by more than 30% in the next 10 years [1]. COPD is
not only a progressive debilitating disease but also a com-
plex condition to manage because of its association with
several comorbidities, which include cardiovascular dis-
ease, hypertension, diabetes, osteoporosis, anxiety and
depression, sleep disorders, lung cancer, and anemia [2].
Previously, epidemiological data showed that over 50% of
1145 patients with COPD had one to two, 15.8% had three to
four, and 6.8% had five or more comorbidities [3]. These
comorbidities contribute to poor health, increased health-
care utilization, all-cause hospitalization, and mortality. It
is well known that patients with COPD are more likely to die
from comorbidities than from the actual disease [4].
Most patients with COPD have similar risk factors, such
as age and smoking. To the best of our knowledge, the in-
dependent association of comorbidities with COPD has
never been studied after adjustment for confounding risk
factors. Furthermore, there appear to have been no com-
parisons of comorbidities in smokers without COPD (non-
COPD smokers) and COPD. .In addition, the majority of
studies of COPD have included only COPD patients who visit
the hospital regularly and not the general population,
potentially leading to selection bias in the evaluation of
COPD comorbidities.
In this study, using data from the general population (the
fifth Korea National Health and Nutrition Examination Sur-
vey [KNHANES V]), we investigated whether COPD is inde-
pendently associated with various comorbidities by
comparing comorbidities in COPD with not only normal
controls but also non-COPD smokers.Figure 1 Flow diagram of patients through the study. FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity.Methods
Sampling strategy in KNHANES V
KNHANES is a nationally representative study designed to
assess the health and nutritional status of civilians in Korea.
KNHANES V was performed from 2010 to 2012. It is based on
data from the Korean Statistical Office census and 3800households from 576 randomly selected survey areas, which
are drawn from a census of the population annually, with
the number selected proportional to the size of each area.
Trained interviewers administer questionnaires on various
health-related information, and subjects self-report their
alcohol and smoking habits. KNHANES uses a complex,
multi-stage probability sample design. The present study
sample represents the total non-institutionalized civilian
population of Korea [5,6]. The present study used the
KNHANES database and was given an exemption from
informed consent by the Institutional Review Board Com-
mittee of our hospital because we used public data pro-
vided by KNHANES(IRB No. 1401-047-547).Definition of COPD
A previous study reported a low prevalence rate of COPD
among females in Korea [7]. Given the expected low rate of
the disease among females, the final analyses included only
male participants. COPD was defined as a former or current
smoker with spirometry-proven airflow limitation (forced
expiratory volume in 1 s [FEV1]/forced vital capacity [FVC]
<0.70). As spirometry is performed only in subjects over 40
years, the cohort consisted of patients older than 40. We
supplemented smoking history to the definition of COPD to
reduce the possibility of including cases with asthma
because there were no post-bronchodilator spirometry re-
sults. The severity of airflow limitation was classified ac-
cording to the Global Initiative for Chronic Obstructive Lung
98 Y.S. Jo et al.disease stage: Stage 1 (mild), Stage 2 (moderate), Stage 3
(severe), and Stage 4 (very severe).
We constructed a simple comorbidity index (range
0e15), where one point was added for each comorbidity
(hypertension, diabetes mellitus [DM], hypercholesterole-
mia, obesity, coronary artery disease, stroke, chronic renal
failure, anemia, osteoporosis, osteoarthritis, rheumatoid
arthritis, atopic dermatitis, lung cancer, pulmonary tuber-
culosis, and depression). A previous study employed a
similar approach [8].
Definition of conditions
Hypertension was defined as mean systolic blood pressure
140 mmHg or mean diastolic blood pressure 90 mmHg on
examination and/or current intake of antihypertensive
drugs [9]. Hypercholesterolemia was defined by total
cholesterol >200 mg/dL or current use of lipid-lowering
drugs [10]. DM was defined by fasting glucose >126 mg/dL
or HbA1c >6.5% or current use of oral hypoglycemic agents
or insulin for glycemic control [11]. Osteoporosis was
defined by current use of osteoporosis medications or a
lumbar spine, total hip, or femur neck T-score <2.5 on
dual-energy X-ray absorptiometry [12]. Anemia was defined
by hemoglobin <12 mg/dL in females and <13 mg/dL inTable 1 Baseline characteristics of male subjects with and wit
Variables COPD
(N Z 744)
Age, years ole, mean  SD 65.02  9.4
BMI, mean  SD 23.73  2.7
Smoking, n (%)
Current smoker 300 (41.32)
Ex-smoker 426 (58.68)
Non-smoker 0 (0)
Spirometry, mean  SD
FEV1, L 2.49  0.54
FEV1,%pred 79.39  13
FVC, L 3.95  0.71
FVC, %pred 90.89  12
Comorbid conditions, n (%)
Hypertension 418 (56.18)
Diabetes mellitus 324 (43.55)
Hypercholesterolemia 581 (78.09)
Obesity 232 (31.18)
Coronary artery disease 22 (2.96)
Stroke 20 (3.69)
Chronic renal failure 8 (1.08)
Anemia 38 (5.11)
Osteoporosis 95 (12.77)
Osteoarthritis 86 (11.56)
Rheumatoid arthritis 10 (1.34)
Atopic dermatitis 23 (3.09)
History of lung cancer 2 (0.27)
History of pulmonary tuberculosis 94 (12.63)
Depression 57 (7.66)
Comorbidity index, mean  SD 2.70  0.44
BMI, body mass index; COPD, chronic obstructive pulmonary disease; F
pred, % of predicted value; SD, standard deviation.males or receiving treatment for the disease [13]. The
definition of obesity in Caucasians is a body mass index
(BMI)  30 kg/m2, but it is currently established that Asians
have a lower BMI range than Caucasians, approximately
2 kg/m2lower. Therefore, the World Health Organization
(WHO) defines obesity in Asians as a 25 kg/m2, and the
Korean Society for the Study of Obesity recommends this
standard [14,15]. Accordingly, we considered subjects with
a BMI 25 kg/m2 as obese according to the WHO and Korean
Society for the Study of Obesity recommendations.
Other comorbidities, including stroke, coronary heart
disease, osteoarthritis, rheumatoid arthritis, pulmonary
tuberculosis, lung cancer, atopic dermatitis, chronic renal
failure, and depression, were defined based on the answers
to self-reported questionnaires asking “Have you been
diagnosed with the disease by a doctor?” (Yes/No), or “Do
you take medicine or treatment for the disease?”Statistical analyses
KNHANES provides population weights [5]. Survey sample
weights were used in all the analyses, except in the first
step of the analysis, to produce estimates that were
representative of the noninstitutionalized population.hout COPD.
Non-COPD
(N Z 3313)
P-value
0 55.06  10.43 <0.001
1 24.43  2.71 <0.001
1192 (36.71) <0.001
1517 (46.72)
538 (16.57)
3.25  0.59 <0.001
.56 92.23  12.05 <0.001
4.18  0.66 <0.001
.39 91.59  11.04 0.1927
1426 (43.04) <0.001
1489 (44.94) 0.489
2654 (80.11) 0.216
1335 (40.30) <0.001
73 (2.20) 0.219
63 (1.90) 0.171
14 (0.42) 0.028
112 (3.38) 0.024
356 (10.75) 0.113
273 (8.24) 0.004
48 (1.45) 0.828
109 (3.29) 0.783
1 (0.03) 0.030
221 (6.67) <0.001
241 (7.27) 0.715
2.54  0.02 0.009
EV1, forced expiratory volume in 1 s; FVC, forced vital capacity; %
The relationship between chronic obstructive pulmonary disease and comorbidities 99In the first step of the analysis, we used the unweighted
data to compare the characteristics and comorbidities of
the COPD cases and non-COPD controls. Pearson’s Chi-
square test was used for categorical variables and an in-
dependent t-test for continuous variables. In the second
step, we determined the prevalence rates of comorbidities
and compared those between the COPD and non-COPD
group using logistic regression with survey design ana-
lyses. In the third step, we performed age-adjusted ana-
lyses. In the fourth step, we used logistic regression
analysis in survey design to adjust for multiple confounders
to investigate whether COPD was an independent risk fac-
tor for each comorbidity. Confounding covariates were
adjusted for each comorbidity as follows:age, BMI, hyper-
tension, hypercholesterolemia and diabetes mellitus for
coronary artery disease and stroke; age and BMI for hy-
pertension, diabetes mellitus, hypercholesterolemia,
osteoporosis, osteoarthritis and depression; and age for
other comorbidities. In the fifth step, we subdivided COPD
cases according to the severity of airflow limitation into
different Global Initiative for Chronic Obstructive Lung
disease stages: Stage 1 (FEV1 80% predicted) and Stage
2e4 (FEV1 <80% predicted). Non-COPD controls were clas-
sified into non-smokers and ever smokers. A P-value <0.05
was considered statistically significant. All analyses were
carried out using STATA version 13.1 (StataCorp, College
Station, Texas, US).
Results
Of 22,679 participants, 9488 underwent a spirometry test.
After excluding participants with self-reported asthma
(n Z 158) and nonsmokers (n Z 290) from those with
airflow limitation (FEV1/FVC < 0.7), 744 (7.84%) COPD cases
and 3313 non-COPD controls were included in the analy-
ses(Fig. 1). Almost 90% of COPD subjects were male, and
more than 90% of females were non-smokers. There were
no females with severe or very severe COPD. Therefore, we
limited the analyses to COPD males.
The baseline characteristics of those with or without
COPD in the unweighted analysis are shown in Table 1. TheTable 2 Prevalence of comorbidities with and without COPD in
Prevalence of comorbidities, % COPD Non-COPD
Hypertension 55.91 40.82
Diabetes mellitus 43.58 43.47
Hypercholesterolemia 76.34 79.24
Obesity 30.47 42.07
Coronary artery disease 3.51 1.53
Stroke 2.1 1.31
Chronic renal failure 0.71 0.36
Anemia 5.04 2.96
Osteoporosis 13.48 10.09
Osteoarthritis 12.51 7.11
Rheumatoid arthritis 1.13 1.22
Atopic dermatitis 3.29 3.29
History of lung cancer 0.13 1.7e-04
History of pulmonary tuberculosis 13.61 5.82
Depression 7.87 7.41COPD group was older, had a lower BMI, and had more
smokers than non-COPD group. The COPD group reported
hypertension, chronic renal failure, anemia, osteoarthritis,
a history of lung cancer, and pulmonary tuberculosis more
frequently than non-COPD group. On the other hand, the
COPD group was less obese than the non-COPD group. In
common with that reported in a previous study [8], the
comorbidity index was significantly higher in the COPD
group compared to the non-COPD group.
Table 2 shows the prevalence rates of comorbidities in
participants with or without COPD. The prevalence rates of
hypertension, DM, hypercholesterolemia, coronary artery
disease, a history of lung cancer, and a history of pulmonary
tuberculosis were 55.91%, 43.58%, 76.34%, 3.51%, 0.13%,
and 13.61%, respectively, among the COPD group. In age-
adjusted analyses, hypertension, coronary artery disease,
anemia, osteoporosis, osteoarthritis, and a history of pul-
monary tuberculosis were significantly more common in the
COPD group than the non-COPD group, whereas obesity was
lower in the COPD group than in the non-COPD group.
After adjusting confounders for each comorbidity, the
prevalence rates of hypertension were higher in both the
non-COPD smoker and COPD groups compared with the
nonsmoker group (adjusted odds ratio [OR], 1.37; 95% CI,
1.09e1.4 in the non-COPD smoker group; aOR, 1.63; 95% CI,
1.13e2.33 in the Stage 1 COPD group; aOR, 1.92; 95% CI,
1.36e2.72 in the Stage 2e4 COPD group). The incidence of
hypertension was statistically greater in the Stage 2e4
COPD group than in the non-COPD smoker group (aOR, 1.42;
95% CI, 1.06e1.91). There were significantly more cases of
pulmonary tuberculosis in the COPD Stage 2e4 group than
in the non-smoker (aOR, 3.38; 95% CI, 1.90e5.99) and non-
COPD smoker groups (aOR, 2.64; 95% CI, 1.71e4.06). In the
age-adjusted analysis, there were significantly more pa-
tients with DM (aOR, 1.28; 95% CI, 1.02e1.60) and depres-
sion (aOR, 1.94; 95% CI, 1.24e3.04) in the non-COPD smoker
group compared with the non-smoker group. However, the
incidence of DM and depression was not significantly
different in the COPD cases compared with the non-
smokers. There were no statistically significant differ-
ences in depression and DM among non-COPD smokers andKorean population.
Age-adjusted OR 95% CI P-value
1.84 1.50e2.25 <0.001
0.83 0.67e1.02 0.079
0.85 0.67e1.07 0.168
0.60 0.49e0.75 <0.001
2.35 1.27e4.35 0.007
1.61 0.84e3.09 0.149
1.98 0.70e5.64 0.199
1.74 1.10e2.75 0.018
1.39 1.03e1.86 0.029
1.87 1.36e2.57 <0.001
0.92 0.40e2.12 0.854
1.00 0.55e1.81 0.993
7.71 0.66e89.88 0.103
2.55 1.86e3.50 <0.001
1.07 0.73e1.56 0.736
Table 3 Comorbid conditions with and without COPD in Korean population.
Variables, % Non-COPD COPD Group Adjusteda Adjustedb
Non-smoker
(N Z 604)
Ever-smoker
(N Z 2709)
Stage 1
(N Z 365)
Stage 2e4
(N Z 379)
OR 95% C p-value OR 95% CI p-value
Hypertension1) 35.56 41.91 55.08 56.72 Non-COPD, smoker 1.37 1.09e 0.008 1 e e
Stage 1 1.63 1.13e 3 0.008 1.20 0.88e1.64 0.248
Stage 2e4 1.92 1.36e 2 <0.001 1.42 1.06e1.91 0.020
Diabetes mellitus2) 9.03 13.51 14.81 21.66 Non-COPD, smoker 1.28 1.02e 0 0.032 1 e e
Stage 1 0.89 0.64e 4 0.498 1.75 0.50e1.12 0.162
Stage 2e4 1.16 0.83e 0 0.390 1.20 0.81e1.76 0.361
Hypercholesterolemia3) 78.00 79.50 77.74 78.74 Non-COPD, smoker 1.07 0.82e 9 0.632 1 e e
Stage 1 0.97 0.66e 2 0.859 0.68 0.46e1.01 0.054
Stage 2e4 1.11 0.74e 6 0.609 0.80 0.53e1.21 0.289
Obesity4) 37.32 43.05 26.31 34.50 Non-COPD, smoker 1.24 0.99e 6 0.061 1 e e
Stage 1 0.72 0.50e 4 0.082 0.58 0.42e0.80 0.001
Stage 2e4 1.03 0.73e 5 0.869 0.83 0.62e1.11 0.205
Coronary artery disease5) 1.38 1.56 3.68 3.35 Non-COPD, smoker 1.13 0.46e 0 0.811 1 e e
Stage 1 1.59 0.48e 0 0.453 1.37 0.51e3.65 0.534
Stage 2e4 1.40 0.43e 7 0.582 1.18 0.46e3.00 0.730
Stroke6) 1.22 1.33 2.91 1.30 Non-COPD, smoker 1.29 0.54e 5 0.573 1 e e
Stage 1 0.95 0.30e 7 0.931 0.72 0.33e1.58 0.410
Stage 2e4 0.47 0.15e 2 0.208 0.35 0.14e0.84 0.020
Anemia7) 4.54 2.63 5.27 4.82 Non-COPD, smoker 0.64 0.34e 0 0.161 1 e e
Stage 1 0.60 0.27e 0 0.194 0.93 0.47e1.84 0.842
Stage 2e4 0.64 0.30e 6 0.249 1.01 0.54e1.87 0.980
Osteoporosis8) 9.88 10.13 12.95 10.66 Non-COPD, smoker 1.12 0.78e 9 0.546 1 e e
Stage 1 0.82 0.49e 9 0.468 0.73 0.39e1.39 0.341
Stage 2e4 1.01 0.61e 8 0.958 1.18 0.69e2.04 0.544
Osteoarthritis9) 7.84 6.95 12.66 8.03 Non-COPD, smoker 0.99 0.67e 6 0.971 1 e e
Stage 1 0.89 0.54e 9 0.668 0.91 0.59e1.40 0.659
Stage 2e4 1.02 0.58e 9 0.953 1.04 0.63e1.71 0.888
Rheumatoid arthritis10) 0.36 1.4 0.73 1.52 Non-COPD, smoker 4.23 0.95e 83 0.058 1 e e
Stage 1 1.36 0.19e 9 0.757 0.33 0.08e1.31 0.114
Stage 2e4 3.14 0.56e 58 0.193 0.76 0.28e2.10 0.603
Atopic dermatitis11) 2.63 3.42 1.59 4.94 Non-COPD, smoker 1.28 0.64e 7 0.487 1 e e
Stage 1 0.74 0.26e 8 0.566 0.58 0.23e1.43 0.234
Stage 2e4 2.28 0.89e 4 0.085 1.78 0.81e3.92 0.152
Pulmonary tuberculosis12) 4.9 6.02 9.20 17.88 Non-COPD, smoker 1.30 0.81e 1 0.276 1 e e
Stage 1 1.46 0.78e 2 0.231 1.14 0.69e1.87 0.613
Stage 2e4 3.38 1.90e 9 0.000 2.64 1.71e4.06 <0.001
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The relationship between chronic obstructive pulmonary disease and comorbidities 101COPD groups. The Stage I COPD group had significantly
lower numbers of obese participants (aOR, 0.58; 95% CI,
0.42e0.80), and the Stage 2e4 COPD group had significantly
lower numbers of participants with stroke (aOR, 0.35; 95%
CI, 0.14e0.84) compared with the non-COPD smoker group.
There were no significant among-group differences in other
comorbidities, including hypercholesterolemia, coronary
artery disease, anemia, osteoporosis, osteoarthritis, rheu-
matoid arthritis, and atopic dermatitis. Due to the lack of
chronic renal failure and lung cancer cases in the non-
smoker group, it was not possible to determine the poten-
tial association between these comorbidities and COPD in
the different groups (Table 3, Fig. 2A and B).Discussion
Interestingly, this study showed that COPD was not inde-
pendently associated with the majority of recognized COPD
comorbidities, except hypertension and pulmonary tuber-
culosis. The prevalence rates of hypertension and pulmo-
nary tuberculosis were 55.91% (95% CI, 1.50e2.25) and
13.61% (95% CI, 1.86e3.50), respectively.
We performed different analyses to investigate the as-
sociation between COPD and comorbidities. When we
adjusted the data only for age, various comorbidities, such
as hypertension, obesity, coronary artery disease, anemia,
osteoporosis, osteoarthritis, and pulmonary tuberculosis,
were significantly associated with COPD, corresponding to
the findings of prior studies [3,16e20]. However, adjusting
the results of the analyses for each comorbidity revealed no
significant between-group differences in the majority of
the above-mentioned comorbidities. In particular, there
were no differences between the non-COPD smokers and
COPD group. Only hypertension and pulmonary tuberculosis
were more common in the COPD group than in the non-
COPD nonsmoker and non-COPD smoker groups. The find-
ings suggest that most comorbidities commonly seen in
COPD patients are due to similar risk factors for the disease
and associated comorbidities. No population-based studies
have compared non-COPD smokers and nonsmokers or
adjusted confounding factors for each comorbidity,
including smoking. Instead, most well-known comorbidities
of COPD are based on studies conducted with subjects who
visit clinics regularly and take appropriate treatment
[3,16e20]. Thus, previous studies have a risk of selection
bias due to the inclusion only of participants with multiple
medical problems and the exclusion of participants from
the general population.
In the present study, there were more hypertensive
participants in the COPD group compared with the non-
COPD group, regardless of smoking history. Several studies
have investigated the association between metabolic syn-
drome (i.e., hypertension, DM, dyslipidemia, and obesity)
and lung function decline [21]. However, the relationship
between metabolic syndrome and COPD remains unclear.
In a recent longitudinal study, hypertension predicted the
acceleration in a decline in the FVC rate, and antihyper-
tensive medication decelerated the FVC decline in hyper-
tensive subjects [22] However, other components of
metabolic syndrome, such as DM, dyslipidemia, and
obesity, did not change the FEV1 or FVC [22]. The previous
Figure 2 A and B:Comorbid conditions with and without COPD in Korean population.
102 Y.S. Jo et al.study did not report the association between metabolic
syndrome and the change in the FEV1/FVC ratio or between
metabolic syndrome and COPD. We found no significant
difference in the presence of DM and dyslipidemia between
the COPD and non-COPD smoker group or between non-
COPD smoker and non-smoker group. Obesity was
also inversely correlated with COPD in the present study.
The mechanism underlying the association betweenhypertension and COPD is not understood. However, as
reported in previous studies [23], in addition to smoking
and systemic inflammation, alveolar microangiopathy and
arterial stiffness, both of which are frequently seen in
hypertension and COPD, could play a role [24e26]. Another
interesting finding of our study was the positive association
between COPD and a history of pulmonary tuberculosis.
Several studies reported that a previous medical diagnosis
The relationship between chronic obstructive pulmonary disease and comorbidities 103of pulmonary tuberculosis is a risk factor for obstructive
lung disease [27,28]. According to one study, a previous
history of pulmonary tuberculosis may result in airway
fibrosis, pleural change, bronchial stenosis or parenchymal
scarring with a subsequent decline in lung function due to
the immune system’s multifaceted response to Mycobac-
terium tuberculosis [29]. In KNHANES, a history of pulmo-
nary tuberculosis is based on self-reporting. Thus, there is
a risk of recall bias and underestimation of the number of
cases due to spontaneously healed pulmonary tuberculosis
that is not recorded. Nevertheless, the present study
showed a consistent association between a history of pul-
monary tuberculosis and COPD, as shown in previous
studies [27,28].
This study has several strengths. First, the results are
based on survey data obtained from KNHANES V, which is
representative of the Korean population, and the study
used survey design analysis. In fact, an inappropriate
analysis of survey data such as NHANES and KNHANES can
result in biased estimates and overstrated significance
levels [30]. However, we incorporate population weights
into analyses to ensure the development of appropriate
estimate. Second, we defined comorbidities objectively
using laboratory results, such as fasting glucose and HbA1c
for DM, and physical findings, such as systolic and diastolic
blood pressure, for hypertension. In most previous studies,
the definition of comorbid conditions of COPD depended on
self-reported questionnaires [8,31,32].
We also acknowledge several limitations in this study.
First, the use of pre-bronchodilator spirometry could have
overestimated the number of COPD subjects and resulted in
the inclusion of asthmatic in the study. To prevent this, we
used smoking history to define COPD and excluded partici-
pants with a history of asthma. Second, KNHANES V data
contains no information on biomarkers for lung disease that
could be used to explain the mechanism between COPD and
comorbidities. Components of systemic inflammation may
account for the systemic manifestations observed in COPD
and worsen comorbidities [25]. Systemic inflammation
could be determined by measuring increased circulating
cytokines, chemokines, and acute phase proteins, such as
C-reactive protein, elevated sedimentation rate, and
fibrinogen [33]. However, we could not evaluate systemic
inflammation because of the absence of the above
mentioned surrogate markers in KNHANES V data. Third,
compared to previous studies including over 3000 COPD
patients, the present study has a relative lack of statistical
power [34,35]. However, the KNHANES sample represents
the total population of Korea; therefore, 744 COPD patients
could represent a large COPD population [5,6]. Fourth, we
were unable to use the number of pack years in the COPD
definition due to the lack of patient history. However, all
COPD patients had a smoking history (current or former).Conclusion
There was a high prevalence rate of comorbidities among
COPD patients in nationally representative data analyzed in
a population-based survey. Among comorbidities only hy-
pertension and a history of pulmonary tuberculosis were
independently associated with COPD after adjustment forage, smoking status, and other confounders. The results
suggest that the majority of comorbidities and COPD might
share the same risk factors including age and smoking
status.
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